| 000 | 01834 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515223427.0 | ||
| 264 | 0 | _c20100824 | |
| 008 | 201008s 0 0 eng d | ||
| 022 | _a1440-1797 | ||
| 024 | 7 |
_a10.1111/j.1440-1797.2009.01256.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFukuda, Akihiro | |
| 245 | 0 | 0 |
_aEffects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. _h[electronic resource] |
| 260 |
_bNephrology (Carlton, Vic.) _cApr 2010 |
||
| 300 |
_a321-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aEplerenone |
| 650 | 0 | 4 | _aFluorescent Antibody Technique |
| 650 | 0 | 4 |
_aIntracellular Signaling Peptides and Proteins _xmetabolism |
| 650 | 0 | 4 |
_aLosartan _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMembrane Proteins _xmetabolism |
| 650 | 0 | 4 |
_aMineralocorticoid Receptor Antagonists _xpharmacology |
| 650 | 0 | 4 |
_aNephrosis, Lipoid _xchemically induced |
| 650 | 0 | 4 |
_aPodocytes _xdrug effects |
| 650 | 0 | 4 |
_aProteinuria _xchemically induced |
| 650 | 0 | 4 | _aPuromycin Aminonucleoside |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aSialoglycoproteins _xmetabolism |
| 650 | 0 | 4 |
_aSpironolactone _xanalogs & derivatives |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aFujimoto, Shouichi | |
| 700 | 1 | _aIwatsubo, Shuji | |
| 700 | 1 | _aKawachi, Hiroshi | |
| 700 | 1 | _aKitamura, Kazuo | |
| 773 | 0 |
_tNephrology (Carlton, Vic.) _gvol. 15 _gno. 3 _gp. 321-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1440-1797.2009.01256.x _zAvailable from publisher's website |
| 999 |
_c19824651 _d19824651 |
||